Robert A Macleod

US Patent:

20120083522, Apr 5, 2012

Filed:

Apr 15, 2010

Appl. No.:

13/262904

Inventors:

Brett P. Monia - Encinitas CA, US
Jeffrey R. Crosby - Carlsbad CA, US
Robert A. MacLeod - San Diego CA, US
Susan M. Freier - San Diego CA, US

Assignee:

Isis Pharmaceuitcals, inc. - Carlsbad CA

International Classification:

A61K 31/7125
A61K 31/7115
A61P 29/00
A61P 19/02
A61P 1/00
A61P 19/06
A61P 37/00
A61P 37/08
A61P 11/06
A61P 35/00
A61P 3/00
A61P 37/06
A61K 31/712
A61P 3/10

US Classification:

514 44 R

Abstract:

Disclosed herein are antisense compounds and methods for modulating Factor XI and modulating an inflammatory disease, disorder or condition in an individual in need thereof. Inflammatory diseases in an individual such as arthritis and colitis can be ameliorated or prevented with the administration of antisense compounds targeted to Factor XI.

US Patent:

20120277284, Nov 1, 2012

Filed:

Mar 30, 2012

Appl. No.:

13/436558

Inventors:

Eric E. Swayze - Encinitas CA, US
Susan M. Freier - San Diego CA, US
Robert A. MacLeod - San Diego CA, US
Youngsoo Kim - San Diego CA, US

International Classification:

A61K 31/7088
C07H 21/04
A61P 21/00
A61K 31/711
A61P 35/04
C07H 21/00
A61P 35/00

US Classification:

514 44 A, 536 245

Abstract:

Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

US Patent:

20130237585, Sep 12, 2013

Filed:

Jul 19, 2011

Appl. No.:

13/811181

Inventors:

C. Frank Bennett - Carlsbad CA, US
Susan M. Freier - San Diego CA, US
Robert A. MacLeod - San Diego CA, US
Sanjay K. Pandey - Encinitas CA, US
Charles A. Thornton - Rochester NY, US
Thurman Wheeler - Rochester NY, US
Seng H. Cheng - Natick MA, US
Andrew Leger - Boston MA, US
Bruce M. Wentworth - Northborough MA, US

Assignee:

UNIVERSITY OF ROCHESTER - Rochester NY
ISIS PHARMACEUTICALS, INC. - Carlsbad CA

International Classification:

C12N 15/113

US Classification:

514 44 A, 536 245

Abstract:

Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.

US Patent:

20130331434, Dec 12, 2013

Filed:

Nov 8, 2011

Appl. No.:

13/884067

Inventors:

Brett P. Monia - Encinitas CA, US
Robert A. MacLeod - Carlsbad CA, US
Jeffrey R. Crosby - Carlsbad CA, US

Assignee:

ISIS PHARMACEUTICALS, INC. - Carlsbad CA

International Classification:

C12N 15/113

US Classification:

514 44 A, 536 245

Abstract:

Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and mesenteric thrombosis. Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.

US Patent:

20200385716, Dec 10, 2020

Filed:

Oct 8, 2019

Appl. No.:

16/595924

Inventors:

Eric E. SWAYZE - Carlsbad CA, US
Susan M. FREIER - Carlsbad CA, US
Robert A. MACLEOD - Carlsbad CA, US
Youngsoo KIM - San Diego CA, US

International Classification:

C12N 15/113
C07H 21/00
C07H 21/04
C12N 15/00
C12N 15/11

Abstract:

Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

US Patent:

20180273577, Sep 27, 2018

Filed:

Sep 23, 2016

Appl. No.:

15/762616

Inventors:

- Carlsbad CA, US
Susan M. FREIER - San Marcos CA, US
Robert A. MACLEOD - San Diego CA, US

International Classification:

C07H 21/04
C12N 15/113
C12Q 1/68
A61K 31/7088

Abstract:

The present embodiments provide methods, compounds, and compositions for inhibiting KRAS expression, which can be useful for treating, preventing, or ameliorating a disease associated with KRAS.

US Patent:

20160348104, Dec 1, 2016

Filed:

May 9, 2016

Appl. No.:

15/149642

Inventors:

- CARLSBAD CA, US
Susan M. Freier - Carlsbad CA, US
Robert A. MacLeod - Carlsbad CA, US
Youngsoo Kim - Carlsbad CA, US

International Classification:

C12N 15/113

Abstract:

Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

US Patent:

20160304877, Oct 20, 2016

Filed:

Aug 11, 2014

Appl. No.:

14/911248

Inventors:

- Carlsbad CA, US
Sanjay K. Pandey - Carlsbad CA, US
Robert A. MacLeod - San Diego CA, US
C. Frank Bennett - Carlsbad CA, US
Susan M. Freier - San Diego CA, US

Assignee:

Ionis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C12N 15/113

Abstract:

Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.

Address:

358 Mainsail Rd, Oceanside, CA 92054

Phone:

(602)2490644

VIN:

KMHCM3AC2BU197157

Make:

HYUNDAI

Model:

ACCENT

Year:

2011